To further investigate the role of Nrf2 in CRC cell resistance to ferroptosis, we treated the RSL3 and Erastin-induced CRC cells with Nrf2 inhibitor, NRF2-IN-1, or Nrf2 activator, TAT-14. The gene discussed is NFE2L2; the disease is colorectal carcinoma.